This final volume had to be written because in today’s regulatory and legal environment, pharmaceutical success no longer depends only on sound formulation and controlled manufacturing, but increasingly on how laboratory results are interpreted, documented, and defended over time. Even when development is scientifically robust and processes are stable, organizations continue to face enforcement actions, inspections, and litigation, most often triggered by laboratory data that cannot withstand retrospective scrutiny. Test results are no longer neutral technical outputs; they function as regulatory statements, governance signals, and legal evidence examined years after generation. Modern inspectors reconstruct events backward, regulators assess patterns rather than isolated results, courts read records without operational context, and undocumented judgment is treated as negligence. A result that once seemed acceptable can later become a liability, and a closed deviation can resurface as a governance failure. This book responds to this new reality by focusing not on analytical methods, but on what happens after testing, explaining how raw material, in-process, finished product, and stability data are misused, overtrusted, or misunderstood, and how OOS and deviations reflect leadership and decision failures before technical ones. It teaches why technically correct laboratories still fail scrutiny and how everyday choices become visible risks. Completing the trilogy, this volume addresses the ultimate need of modern pharmaceutical systems: ensuring that laboratory data remains defensible, credible, and trustworthy long after inspections end, personnel change, and context disappears.